Vogt-Koyanagi-Harada disease (VKHD) is a multisystemic disorder characterized by granulomatous panuveitis with exudative retinal detachments, often associated with neurologic and cutaneous manifestations. Therapy relies mainly on the use of corticosteroids, administrated as oral or intravenous high-dose pulses, and immunosuppressants. However, since macular edema and retinal detachment can often be refractory to systemic therapies, intravitreal triamcinolone acetate has been used successfully. Herein, we report the first case of refractory bilateral panuveitis in a young patient with VKHD successfully treated with dexamethasone intravitreal implant.
Latronico, M. E., Rigante, D., Cantarini, L., Caso, F., Traversi, C., Franceschini, R., Bilateral dexamethasone intravitreal implant (Ozurdex®) in a young patient with Vogt-Koyanagi-Harada disease and refractory uveitis, <<CLINICAL RHEUMATOLOGY>>, 2015; 34 (6): 1145-1148. [doi:10.1007/s10067-014-2623-1] [http://hdl.handle.net/10807/87531]
Bilateral dexamethasone intravitreal implant (Ozurdex®) in a young patient with Vogt-Koyanagi-Harada disease and refractory uveitis
Rigante, DonatoSecondo
;
2015
Abstract
Vogt-Koyanagi-Harada disease (VKHD) is a multisystemic disorder characterized by granulomatous panuveitis with exudative retinal detachments, often associated with neurologic and cutaneous manifestations. Therapy relies mainly on the use of corticosteroids, administrated as oral or intravenous high-dose pulses, and immunosuppressants. However, since macular edema and retinal detachment can often be refractory to systemic therapies, intravitreal triamcinolone acetate has been used successfully. Herein, we report the first case of refractory bilateral panuveitis in a young patient with VKHD successfully treated with dexamethasone intravitreal implant.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
